Such effects of KLF12 on breast cancer cells appeared to stem from its ability to inhibit the stability of p53 by reducing p300-mediated acetylation of p53 and to directly inhibit the transcription p21 by binding to the promoter of p21. This data may further our understanding of the molecular mechanism of KLF12 in breast cancer. Here, CDKN1A is linked to breast carcinoma.